Compound ID | 1869
Synonym(s): Sulopenem etzadroxil | CP-70,429 | CP-65,207
Class: Beta-lactam (penem)
| Spectrum of activity: | Gram-positive & Gram-negative | 
| Details of activity: | Binds to bacterial penicillin-binding proteins and interferes with bacterial cell wall integrity and synthesis. Less active than carbapenems against Gram-negative bacteria, no activity against Pseudomonas aeruginosa | 
| Description: | Synthetic compound, fixed combination with probenicid. Oral and iv formulation,not non-inferior to ertapenem in a Phase 3 clinical study in complicated intraabdominal infections and not non-inferior to ciprofloxacin in treatment of uUTI | 
| Institute where first reported: | Pfizer, Iterum | 
| Year first mentioned: | 1989 | 
| Highest developmental phase: | Approved by FDA in 2024 | 
| Development status: | Approved | 
| Chemical structure(s): | |||||||||||
| 
 | 
 |